Safety and efficacy of pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis and carrying a telomere-related gene mutation

Aurélien Justet; Dymph Klay; Raphaël Porcher; Vincent Cottin; Kais Ahmad; Maria Molina Molina; Hilario Nunes; Martine Reynaud-Gaubert; Jean Marc Naccache; Effrosyni Manali; Antoine Froidure; Stéphane Jouneau; Lidwine Wemeau; Claire Andrejak; Anne Gondouin; Sandrine Hirschi; Elodie Blanchard; Benjamin Bondue1; Philippe Bonniaud; Cécile Tromeur; Grégoire Prévot; Sylvain Marchand-Adam; Manuela Funke-Chambour; Anne Sophie Gamez; Ibrahima Ba; Spyridon Papiris; Jan Grutters; Bruno Crestani; Coline Van Moorsel; Caroline Kannengiesser

doi:10.1183/13993003.03198-2020

Safety and efficacy of pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis and carrying a telomere-related gene mutation

Aurélien Justet
, Dymph Klay
, Raphaël Porcher^*
, Vincent Cottin
, Kais Ahmad
, Maria Molina Molina
, Hilario Nunes
, Martine Reynaud-Gaubert
, Jean Marc Naccache
, Effrosyni Manali
, Antoine Froidure
, Stéphane Jouneau
, Lidwine Wemeau
, Claire Andrejak
, Anne Gondouin
, Sandrine Hirschi
, Elodie Blanchard
, Benjamin Bondue1
, Philippe Bonniaud
, Cécile Tromeur

Grégoire Prévot, Sylvain Marchand-Adam, Manuela Funke-Chambour, Anne Sophie Gamez, Ibrahima Ba, Spyridon Papiris, Jan Grutters, Bruno Crestani, Coline Van Moorsel, Caroline Kannengiesser

^*Corresponding author for this work

Research output: Contribution to journal › Letter › Academic › peer-review

7 Citations (Scopus)

Original language	English
Article number	2003198
Journal	European Respiratory Journal
Volume	57
Issue number	2
DOIs	https://doi.org/10.1183/13993003.03198-2020
Publication status	Published - 1 Feb 2021
Externally published	Yes

Access to Document

10.1183/13993003.03198-2020

Cite this

Justet, A., Klay, D., Porcher, R., Cottin, V., Ahmad, K., Molina, M. M., Nunes, H., Reynaud-Gaubert, M., Naccache, J. M., Manali, E., Froidure, A., Jouneau, S., Wemeau, L., Andrejak, C., Gondouin, A., Hirschi, S., Blanchard, E., Bondue1, B., Bonniaud, P., ... Kannengiesser, C. (2021). Safety and efficacy of pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis and carrying a telomere-related gene mutation. European Respiratory Journal, 57(2), Article 2003198. https://doi.org/10.1183/13993003.03198-2020

@article{09e94aefae474124ab85cf8c9766fed1,

title = "Safety and efficacy of pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis and carrying a telomere-related gene mutation",

author = "Aur{\'e}lien Justet and Dymph Klay and Rapha{\"e}l Porcher and Vincent Cottin and Kais Ahmad and Molina, \{Maria Molina\} and Hilario Nunes and Martine Reynaud-Gaubert and Naccache, \{Jean Marc\} and Effrosyni Manali and Antoine Froidure and St{\'e}phane Jouneau and Lidwine Wemeau and Claire Andrejak and Anne Gondouin and Sandrine Hirschi and Elodie Blanchard and Benjamin Bondue1 and Philippe Bonniaud and C{\'e}cile Tromeur and Gr{\'e}goire Pr{\'e}vot and Sylvain Marchand-Adam and Manuela Funke-Chambour and Gamez, \{Anne Sophie\} and Ibrahima Ba and Spyridon Papiris and Jan Grutters and Bruno Crestani and \{Van Moorsel\}, Coline and Caroline Kannengiesser",

note = "Funding Information: Conflict of interest: A. Justet reports grants from Roche, personal fees from Boeringher Ingelheim, outside the submitted work. D. Klay has nothing to disclose. R. Porcher has nothing to disclose. V. Cottin reports personal fees for advisory board work and lectures, and non-financial support for meeting attendance from Actelion, grants, personal fees for consultancy and lectures, and non-financial support for meeting attendance from Boehringer Ingelheim, personal fees for advisory board and data monitoring committee work from Bayer/MSD and Galapagos, personal fees for advisory board work and lectures from Novartis, personal fees for consultancy, lectures, steering committee and data monitoring committee work, and non-financial support for meeting attendance from Roche/Promedior, personal fees for lectures from Sanofi and AstraZeneca, personal fees for data monitoring committee work from Celgene and Galecto, personal fees for advisory board work from Shionogi, outside the submitted work. K. Ahmad reports personal fees from Roche and Boeringher Ingelheim, outside the submitted work. M. Molina-Molina reports grants and personal fees from Roche, Boehringer Ingelheim and Esteve-Teijin, personal fees from Chiesi, Pfizer and Galapagos, outside the submitted work. H. Nunes reports personal fees from Intermune, Roche, Boehringer Ingelheim and Sanofi, outside the submitted work. M. Reynaud-Gaubert has nothing to disclose. J.M. Naccache has nothing to disclose. E. Manali reports grants and personal fees from Roche and Boehringer Ingelheim, during the conduct of the study. A. Froidure reports grants, personal fees and non-financial support from Roche and Boehringer Ingelheim, personal fees and non-financial support from AstraZeneca, personal fees from GlaxoSmithKline, outside the submitted work. S. Jouneau reports fees, funding or reimbursement for national and international conferences, boards, expert or opinion groups, research projects over the past 3 years from AIRB, Bellorophon Therapeutics, Biogen, Boehringer, Chiesi, Fibrogen, Galecto Biotech, Genzyme, Gilead, LVL, Novartis, Olam Pharm, Pfizer, Pliant Therapeutics, Roche, Sanofi and Savara-Serendex. L. Wemeau has nothing to disclose. C. Andrejak has nothing to disclose. A. Gondouin has nothing to disclose. S. Hirschi has nothing to disclose. E. Blanchard has nothing to disclose. B. Bondue reports grants and personal fees from Boeringher Ingleheim and Hoffman La Roche, outside the submitted work. P. Bonniaud reports personal fees from Roche, Novartis, Boeringher, TEVA and AstraZeneca, outside the submitted work. C. Tromeur has nothing to disclose. G. Prevot reports personal fees from Actelion, Bayer, Boehringer Ingelheim and Roche, outside the submitted work. S. Marchand-Adam has nothing to disclose. M. Funke-Chambour reports grants from Roche and Boehringer Ingelheim, during the conduct of the study. A.S. Gamez has nothing to disclose. I. Ba has nothing to disclose. S. Papiris reports grants and personal fees from Roche and Boehringer Ingelheim, during the conduct of the study. J. Grutters has nothing to disclose. B. Crestani reports personal fees from AstraZeneca and Sanofi, grants and personal fees from Boeringher Ingelheim and Roche, personal fees and non-financial support from BMS, outside the submitted work. C. van Moorsel has nothing to disclose. C. Kannengiesser has nothing to disclose. R. Borie reports grants and personal fees from Boeringher Ingelheim and Roche, personal fees from Savapharma, outside the submitted work.",

year = "2021",

month = feb,

day = "1",

doi = "10.1183/13993003.03198-2020",

language = "English",

volume = "57",

journal = "European Respiratory Journal",

issn = "0903-1936",

publisher = "European Respiratory Society",

number = "2",

}

Justet, A, Klay, D, Porcher, R, Cottin, V, Ahmad, K, Molina, MM, Nunes, H, Reynaud-Gaubert, M, Naccache, JM, Manali, E, Froidure, A, Jouneau, S, Wemeau, L, Andrejak, C, Gondouin, A, Hirschi, S, Blanchard, E, Bondue1, B, Bonniaud, P, Tromeur, C, Prévot, G, Marchand-Adam, S, Funke-Chambour, M, Gamez, AS, Ba, I, Papiris, S, Grutters, J, Crestani, B, Van Moorsel, C & Kannengiesser, C 2021, 'Safety and efficacy of pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis and carrying a telomere-related gene mutation', European Respiratory Journal, vol. 57, no. 2, 2003198. https://doi.org/10.1183/13993003.03198-2020

TY - JOUR

T1 - Safety and efficacy of pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis and carrying a telomere-related gene mutation

AU - Justet, Aurélien

AU - Klay, Dymph

AU - Porcher, Raphaël

AU - Cottin, Vincent

AU - Ahmad, Kais

AU - Molina, Maria Molina

AU - Nunes, Hilario

AU - Reynaud-Gaubert, Martine

AU - Naccache, Jean Marc

AU - Manali, Effrosyni

AU - Froidure, Antoine

AU - Jouneau, Stéphane

AU - Wemeau, Lidwine

AU - Andrejak, Claire

AU - Gondouin, Anne

AU - Hirschi, Sandrine

AU - Blanchard, Elodie

AU - Bondue1, Benjamin

AU - Bonniaud, Philippe

AU - Tromeur, Cécile

AU - Prévot, Grégoire

AU - Marchand-Adam, Sylvain

AU - Funke-Chambour, Manuela

AU - Gamez, Anne Sophie

AU - Ba, Ibrahima

AU - Papiris, Spyridon

AU - Grutters, Jan

AU - Crestani, Bruno

AU - Van Moorsel, Coline

AU - Kannengiesser, Caroline

N1 - Funding Information: Conflict of interest: A. Justet reports grants from Roche, personal fees from Boeringher Ingelheim, outside the submitted work. D. Klay has nothing to disclose. R. Porcher has nothing to disclose. V. Cottin reports personal fees for advisory board work and lectures, and non-financial support for meeting attendance from Actelion, grants, personal fees for consultancy and lectures, and non-financial support for meeting attendance from Boehringer Ingelheim, personal fees for advisory board and data monitoring committee work from Bayer/MSD and Galapagos, personal fees for advisory board work and lectures from Novartis, personal fees for consultancy, lectures, steering committee and data monitoring committee work, and non-financial support for meeting attendance from Roche/Promedior, personal fees for lectures from Sanofi and AstraZeneca, personal fees for data monitoring committee work from Celgene and Galecto, personal fees for advisory board work from Shionogi, outside the submitted work. K. Ahmad reports personal fees from Roche and Boeringher Ingelheim, outside the submitted work. M. Molina-Molina reports grants and personal fees from Roche, Boehringer Ingelheim and Esteve-Teijin, personal fees from Chiesi, Pfizer and Galapagos, outside the submitted work. H. Nunes reports personal fees from Intermune, Roche, Boehringer Ingelheim and Sanofi, outside the submitted work. M. Reynaud-Gaubert has nothing to disclose. J.M. Naccache has nothing to disclose. E. Manali reports grants and personal fees from Roche and Boehringer Ingelheim, during the conduct of the study. A. Froidure reports grants, personal fees and non-financial support from Roche and Boehringer Ingelheim, personal fees and non-financial support from AstraZeneca, personal fees from GlaxoSmithKline, outside the submitted work. S. Jouneau reports fees, funding or reimbursement for national and international conferences, boards, expert or opinion groups, research projects over the past 3 years from AIRB, Bellorophon Therapeutics, Biogen, Boehringer, Chiesi, Fibrogen, Galecto Biotech, Genzyme, Gilead, LVL, Novartis, Olam Pharm, Pfizer, Pliant Therapeutics, Roche, Sanofi and Savara-Serendex. L. Wemeau has nothing to disclose. C. Andrejak has nothing to disclose. A. Gondouin has nothing to disclose. S. Hirschi has nothing to disclose. E. Blanchard has nothing to disclose. B. Bondue reports grants and personal fees from Boeringher Ingleheim and Hoffman La Roche, outside the submitted work. P. Bonniaud reports personal fees from Roche, Novartis, Boeringher, TEVA and AstraZeneca, outside the submitted work. C. Tromeur has nothing to disclose. G. Prevot reports personal fees from Actelion, Bayer, Boehringer Ingelheim and Roche, outside the submitted work. S. Marchand-Adam has nothing to disclose. M. Funke-Chambour reports grants from Roche and Boehringer Ingelheim, during the conduct of the study. A.S. Gamez has nothing to disclose. I. Ba has nothing to disclose. S. Papiris reports grants and personal fees from Roche and Boehringer Ingelheim, during the conduct of the study. J. Grutters has nothing to disclose. B. Crestani reports personal fees from AstraZeneca and Sanofi, grants and personal fees from Boeringher Ingelheim and Roche, personal fees and non-financial support from BMS, outside the submitted work. C. van Moorsel has nothing to disclose. C. Kannengiesser has nothing to disclose. R. Borie reports grants and personal fees from Boeringher Ingelheim and Roche, personal fees from Savapharma, outside the submitted work.

PY - 2021/2/1

Y1 - 2021/2/1

UR - https://www.scopus.com/pages/publications/85101250719

U2 - 10.1183/13993003.03198-2020

DO - 10.1183/13993003.03198-2020

M3 - Letter

C2 - 33214205

AN - SCOPUS:85101250719

SN - 0903-1936

VL - 57

JO - European Respiratory Journal

JF - European Respiratory Journal

IS - 2

M1 - 2003198

ER -

Safety and efficacy of pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis and carrying a telomere-related gene mutation

Access to Document

Other files and links

Cite this